The survival of BC patients is influenced by clinical factors such as tumor stage, tumor grade, estrogen receptor (ER) and progesterone receptor (PR) status, as well as human epidermal growth factor receptor 2 (HER2) status [3]. This evidence concerns the gene ERBB2 and neoplasm.